Germline BRCA Mutations Associated With Increased Likelihood of Secondary Cytoreductive Surgery in Ovarian Cancer
Experts at the 2022 SGO Annual Meeting announce germline BRCA mutation carriers are more likely to undergo secondary cytoreduction probably due to lower volume disease at recurrence.
Investigators compared eligibility and rate of secondary cytoreduction among 147 patients with ovarian cancer, both BRCA mutation carriers and non-carriers, with platinum-sensitive ovarian cancer recurrence.
Among the 147 patients, 26.5% displayed germ line BRCA mut8, and 5.5% patients displayed somatic BRCA mut28. Notably, 6m median time to recurrence31 (21.1%) secondary cytoreduction (SCC)41 (27.8%) eligible for SCC, according to researchers at the presentation, according to findings presented by Yfat Kadan, MD, and fellow investigators.
After adjusting for number of recurrence lesions, it was reported no other factor was significantly prognostic for SCC.
To conclude, germline BRCA mutation carriers are more likely to undergo secondary cytoreduction probably due to lower volume disease at recurrence.
